2PATIX, based in Houston, Texas, is a regenerative emergency medicine company developing biologic therapies for myocardial infarction, cerebral infarction, spinal cord injury, traumatic brain injury and acute kidney injury.  Each of these problems have the shared pathophysiology of ischemia/reperfusion injury (IRI) and have no FDA approved disease modifying drugs.  We aim to change the treatment paradigm in emergency care through two proprietary hepatocyte growth factor (HGF) mimetic biologics—2PAT-301 and 2PAT-401—engineered for rapid, systemic protection of vulnerable organs at the time of ischemic insult.